Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05970666
Other study ID # 23-OBU-FJ-HCC-II-012
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 15, 2023
Est. completion date November 15, 2026

Study information

Verified date February 2024
Source The First Affiliated Hospital of Xiamen University
Contact Jianbo Chen
Phone 15605921022
Email 274439002@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma


Recruitment information / eligibility

Status Recruiting
Enrollment 71
Est. completion date November 15, 2026
Est. primary completion date November 15, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age: 18 ~ 75, both male and female; 2. Strictly comply with the primary liver cancer diagnosis and treatment standard (2022 edition) clinical diagnosis criteria or primary hepatocellular carcinoma diagnosed by pathological histology or cytology examination, and at least one measurable lesions (according to the RECIST1.1 standard, the spiral CT scan of 10mm or short diameter of 15mm); 3. Patients without previous systematic treatment and inoperable resection / radical ablation surgery, but who can tolerate TACE; 4. The CNLC stage is ?a-?b stage; 5. The Child-Pugh grade of liver function is A grade or B grade (5-7 points); 6. The ECOG PS score is 0-1 points; 7. Expected survival period of 12 weeks; 8. If the patient has active hepatitis B virus (HBV) infection: HBV-deoxyribonucleic acid (DNA) must be <2000 IU / mL (if the study site has only copy / mL testing units, Must be <12500 copy / mL), And received at least 14 days before initiating anti-HBV treatment (according to local standard therapy, e. g. entecavir) and willing to receive antiviral treatment throughout the study; hepatitis C virus (HCV) ribonucleic acid (RNA) positive patients must receive antiviral treatment according to local standard treatment guidelines and liver function within grade CTCAE 1 elevation; 9. Main organs function are normal and meet the following criteria: (1) The blood routine examination standards should be met with: (no blood transfusion within 14 days) A. Hemoglobin (HB), 90g / L, B. White blood cell count (WBC) 3109 / L C. Absolute neutrophil count (ANC) 1.5109 / L, D. Platelet (PLT) 80109 / L;(2) Biochemical examination shall meet the following standards: A. Bilirubin (BIL) <1.5 times the upper limit of normal value (ULN); B. Glutamic gamma aminotransferase (ALT) and glutamate aminotransferase AST <5 ULN; C. Serum creatinine (Cr)=1.5ULN; 10. Women of childbearing age must have negative pregnancy test (serum) or urine HCG within 7 days before enrollment and are willing to use appropriate contraception during treatment and 24 weeks after the last administration of test drug; for men, surgical sterilization or agree to use appropriate contraception during and 24 weeks after the last administration of trial drug; 11. The subjects volunteered to join the study and had good compliance with the follow-up. Exclusion Criteria: 1. Pregnant or lactating women; 2. The pathology is clearly cholangiocytic carcinoma or mixed cell carcinoma; 3. Diffuse liver cancer; 4. Patients with autoimmune diseases, organ / hematopoietic stem cell transplantation or other malignant tumors (except for cured basal skin cell carcinoma and cervix carcinoma in situ); 5. Patients with consciousness disorders or unable to cooperate with the treatment, combined with patients with mental illness; 6. Patients who have participated in other clinical trials in the recent three months; 7. Previous history of other malignancies or have received targeted therapy and other PD-1 / PD-L1 inhibitor therapy; 8. Received major surgery or chemotherapy or other systemic therapy for target lesions (including not limited to radiation therapy, ablation therapy, etc.) within 1 month prior to enrollment; 9. Use of immunosuppressants or systemic hormone therapy within 14 days before enrollment to achieve immunosuppressive purposes (dose> 10mg / day prednisone or other efficacy hormones); 10. Liver function was graded as Child-Pugh C, which could not be improved by liver care treatment; 11. esophageal (gastric fundus) varices rupture and bleeding within 1 month before treatment; 12. Uncorrectable coagulopathy and severe blood abnormalities, with severe bleeding tendency. Platelet count <50109 / L and severe coagulation abnormalities against surgery (anticoagulation therapy and / or anticoagulant therapy should be stopped for more than 1 week before radiation therapy); 13. A stubborn amount of ascites, pleural fluid, malignant fluid; 14. Active infection, especially the inflammation of the biliary tract system; 15. Severe functional failure of the liver, kidney, heart, lung, brain and other major organs; 16. Previously allergic to PD-1 / PD-L1 mAb / any component of the targeted drug or other similar trials; 17. Patients with hypertension who cannot be reduced to the normal range by antihypertensive medication (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg); 18. Previous severe cardiovascular disease, including but not limited to the following diseases: myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including 450 ms in QTc men and 470 ms in women); cardiac dysfunction by NYHA, or cardiac ultrasound indicating left ventricular ejection fraction (LVEF) <50%; 19. Patients with positive urinary protein (urinary protein test of 2 + or above, or 24-hour urinary protein quantification of> 1.0g); 20. Failure to swallow tablets, malabsorption syndrome, or any condition affecting gastrointestinal absorption; 21. According to the discretion of the investigator, patients with other concomitant diseases that seriously endanger patient safety or affect the completion of the study; 22. Patients with radiotherapy, targeted therapy, and other contraindications to immunotherapy.

Study Design


Intervention

Drug:
TACE with adebrelimab and bevacizumab
TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);

Locations

Country Name City State
China The First Affiliated Hospital of Xiamen University Xiamen Fujian

Sponsors (2)

Lead Sponsor Collaborator
The First Affiliated Hospital of Xiamen University Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate(ORR) Refers to the proportion of all subjects with the best overall response (BOR) as complete remission (CR) or partial remission (PR) according to mRECIST 1.1 criteria. Up to 2 years
Primary Occurence of AE and SAE Occurence of Adverse Event (AE) and Serious Adverse Event (SAE) (NCI CTCAE 5.0) Up to 2 years
Secondary Radical (R0) resection rate after conversion therapy The cut margin had no residual cancer cells Up to 2 years
Secondary percent conversion The ates of conversion to operable patients in inoperable patients Up to 2 years
Secondary Pathological complete response rate (pCR) The rate of no remaining tumor cells in the excised tissue samples Up to 2 years
Secondary Major pathological response rate (MPR) The ratio of the tumor cells active in the removed tissue samples is less than 10%. Up to 2 years
Secondary Progression-free survival (PFS) PFS was defined as the subject's date from the date of the first dose to the date of the first documented tumor progression (as assessed by mRECIST criteria, with or without continuation of treatment) or the date of death from any cause, whichever occurred first. Up to 2 years
Secondary Disease control rate(DCR) Refers to the proportion of all subjects with the best overall response (BOR) according to mRECIST criteria as complete remission (CR), partial remission (PR) and stable disease (SD). Up to 2 years
Secondary Relapse-free survival time (RFS) Time from date of cure surgery to time of recurrence or death Up to 2 years
Secondary Overall survival(OS) Defined as the time from the date of the first dose to the death of the subject from any cause. Up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2